Month: May 2026

Recombinant Albumin Enhances Lentiviral Vector Stability During Downstream Processing

By

Lentiviral vectors (LVVs) remain one of the most widely used gene delivery systems for ex vivo cell therapy manufacturing, including CAR-T workflows, and are increasingly being explored for in vivo gene delivery applications. However, enveloped viral particles are highly sensitive to manufacturing-related stress during downstream processing. Operations such as tangential flow filtration (TFF), sterile filtration, …

Enhanced Cryopreservation of Therapeutically Relevant Cells

By

Reduced-DMSO cryopreservation workflows often compromise post-thaw viability, expansion, and functional cell attributes due to increased cellular stress during freeze/thaw. In a comparative study across T cells, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), InVitria® evaluated whether recombinant human serum albumin (rHSA) could improve cryopreservation performance relative to plasma-derived HSA (pHSA) and albumin-free …

InVitria Presents ASGCT 2026 Data on rHSA for Lentiviral Vector Manufacturing

By

FOR IMMEDIATE RELEASE InVitria Presents New Data at ASGCT 2026 on Recombinant Human Serum Albumin for Higher Lentiviral Vector Titers and Improved Cell Therapy Manufacturing JUNCTION CITY, Kan., May 12, 2026 — InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for advanced therapy manufacturing, announced its participation in the American Society of Gene …